1. Home
  2. CYRX vs TRDA Comparison

CYRX vs TRDA Comparison

Compare CYRX & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CryoPort Inc.

CYRX

CryoPort Inc.

HOLD

Current Price

$8.05

Market Cap

421.6M

Sector

Health Care

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$12.68

Market Cap

438.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYRX
TRDA
Founded
1999
2016
Country
United States
United States
Employees
1100
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
421.6M
438.8M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
CYRX
TRDA
Price
$8.05
$12.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
2
Target Price
$12.94
$20.00
AVG Volume (30 Days)
341.9K
189.4K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
156.22
N/A
EPS
1.40
N/A
Revenue
$176,177,000.00
$25,421,000.00
Revenue This Year
$9.71
$51.37
Revenue Next Year
$9.56
$46.98
P/E Ratio
$4.99
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.63
$4.93
52 Week High
$11.45
$12.93

Technical Indicators

Market Signals
Indicator
CYRX
TRDA
Relative Strength Index (RSI) 37.26 59.74
Support Level $6.57 $9.59
Resistance Level $8.45 N/A
Average True Range (ATR) 0.51 0.84
MACD 0.04 0.07
Stochastic Oscillator 25.71 85.96

Price Performance

Historical Comparison
CYRX
TRDA

About CYRX CryoPort Inc.

CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: